{"title":"反复射频消融在头颈部腺样囊性癌肺转移患者中的作用:16例289例肿瘤的长期单中心研究","authors":"Yuki Omori, Masashi Fujimori, Takashi Yamanaka, Ken Nakajima, Naritaka Matsushita, Seiya Kishi, Hiroaki Kato, Chisami Nagata, Hikari Fukui, Ryosuke Shima, Toru Ogura, Hajime Sakuma","doi":"10.22575/interventionalradiology.2024-0015","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To retrospectively assess the clinical outcomes of repeated radiofrequency ablation for lung metastases of head and neck adenoid cystic carcinoma. <b>Material and Methods:</b> Consecutive 16 patients (mean age, 55.3 years) who were treated with radiofrequency ablation for 289 lung metastases were included. A 17-gauge electrode was used in all radiofrequency ablation procedures and placed under computed tomography fluoroscopic guidance. Evaluated were safety, technical success, local tumor control, and survival. <b>Results:</b> In total, 143 radiofrequency ablation sessions were performed for 289 lung metastases. One session of radiofrequency ablation was not completed due to pleural hemorrhage during the procedure, resulting in a technical success rate of 99.3% (142/143). Major complications (pneumothorax and hemorrhage) occurred in 40 sessions (27.9%, 40/143). During the mean follow-up period of 5.5 ± 3.6 years (range, 0.4-13.4 years), local tumor progression was observed in 16 tumors (5.5%, 16/289) and repeated radiofrequency ablation (93.8%, 15/16) or metastasectomy (6.2%, 1/16) was performed for all locally progressed lung metastases. The local tumor control rates were 97.1% (95% confidence interval, 95.1%-99.2%) and 89.5% (95% confidence interval, 84.0%-95.0%) at 1- and 5-year. Median survival time after initial lung radiofrequency ablation was 9.8 years and 1-, 3-, 5-, and 10-year overall survival rates were 100% (95% confidence interval, 100%), 91.7% (95% confidence interval, 76.0%-100%), 64.3% (95% confidence interval, 35.7%-92.9%), and 35.7% (95% confidence interval, 0%-70.8%), respectively. <b>Conclusions:</b> Repeated radiofrequency ablation for multiple lung metastases of adenoid cystic carcinoma was feasible and safe and may allow survival with good local control of lung metastases.</p>","PeriodicalId":73503,"journal":{"name":"Interventional radiology (Higashimatsuyama-shi (Japan)","volume":"10 ","pages":"e20240015"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078032/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of Repeated Radiofrequency Ablation for Patients with Lung Metastases of Head and Neck Adenoid Cystic Carcinoma: Long-term Single-center Study in 16 Patients with 289 Tumors.\",\"authors\":\"Yuki Omori, Masashi Fujimori, Takashi Yamanaka, Ken Nakajima, Naritaka Matsushita, Seiya Kishi, Hiroaki Kato, Chisami Nagata, Hikari Fukui, Ryosuke Shima, Toru Ogura, Hajime Sakuma\",\"doi\":\"10.22575/interventionalradiology.2024-0015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> To retrospectively assess the clinical outcomes of repeated radiofrequency ablation for lung metastases of head and neck adenoid cystic carcinoma. <b>Material and Methods:</b> Consecutive 16 patients (mean age, 55.3 years) who were treated with radiofrequency ablation for 289 lung metastases were included. A 17-gauge electrode was used in all radiofrequency ablation procedures and placed under computed tomography fluoroscopic guidance. Evaluated were safety, technical success, local tumor control, and survival. <b>Results:</b> In total, 143 radiofrequency ablation sessions were performed for 289 lung metastases. One session of radiofrequency ablation was not completed due to pleural hemorrhage during the procedure, resulting in a technical success rate of 99.3% (142/143). Major complications (pneumothorax and hemorrhage) occurred in 40 sessions (27.9%, 40/143). During the mean follow-up period of 5.5 ± 3.6 years (range, 0.4-13.4 years), local tumor progression was observed in 16 tumors (5.5%, 16/289) and repeated radiofrequency ablation (93.8%, 15/16) or metastasectomy (6.2%, 1/16) was performed for all locally progressed lung metastases. The local tumor control rates were 97.1% (95% confidence interval, 95.1%-99.2%) and 89.5% (95% confidence interval, 84.0%-95.0%) at 1- and 5-year. Median survival time after initial lung radiofrequency ablation was 9.8 years and 1-, 3-, 5-, and 10-year overall survival rates were 100% (95% confidence interval, 100%), 91.7% (95% confidence interval, 76.0%-100%), 64.3% (95% confidence interval, 35.7%-92.9%), and 35.7% (95% confidence interval, 0%-70.8%), respectively. <b>Conclusions:</b> Repeated radiofrequency ablation for multiple lung metastases of adenoid cystic carcinoma was feasible and safe and may allow survival with good local control of lung metastases.</p>\",\"PeriodicalId\":73503,\"journal\":{\"name\":\"Interventional radiology (Higashimatsuyama-shi (Japan)\",\"volume\":\"10 \",\"pages\":\"e20240015\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078032/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interventional radiology (Higashimatsuyama-shi (Japan)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22575/interventionalradiology.2024-0015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/28 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional radiology (Higashimatsuyama-shi (Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22575/interventionalradiology.2024-0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/28 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Role of Repeated Radiofrequency Ablation for Patients with Lung Metastases of Head and Neck Adenoid Cystic Carcinoma: Long-term Single-center Study in 16 Patients with 289 Tumors.
Purpose: To retrospectively assess the clinical outcomes of repeated radiofrequency ablation for lung metastases of head and neck adenoid cystic carcinoma. Material and Methods: Consecutive 16 patients (mean age, 55.3 years) who were treated with radiofrequency ablation for 289 lung metastases were included. A 17-gauge electrode was used in all radiofrequency ablation procedures and placed under computed tomography fluoroscopic guidance. Evaluated were safety, technical success, local tumor control, and survival. Results: In total, 143 radiofrequency ablation sessions were performed for 289 lung metastases. One session of radiofrequency ablation was not completed due to pleural hemorrhage during the procedure, resulting in a technical success rate of 99.3% (142/143). Major complications (pneumothorax and hemorrhage) occurred in 40 sessions (27.9%, 40/143). During the mean follow-up period of 5.5 ± 3.6 years (range, 0.4-13.4 years), local tumor progression was observed in 16 tumors (5.5%, 16/289) and repeated radiofrequency ablation (93.8%, 15/16) or metastasectomy (6.2%, 1/16) was performed for all locally progressed lung metastases. The local tumor control rates were 97.1% (95% confidence interval, 95.1%-99.2%) and 89.5% (95% confidence interval, 84.0%-95.0%) at 1- and 5-year. Median survival time after initial lung radiofrequency ablation was 9.8 years and 1-, 3-, 5-, and 10-year overall survival rates were 100% (95% confidence interval, 100%), 91.7% (95% confidence interval, 76.0%-100%), 64.3% (95% confidence interval, 35.7%-92.9%), and 35.7% (95% confidence interval, 0%-70.8%), respectively. Conclusions: Repeated radiofrequency ablation for multiple lung metastases of adenoid cystic carcinoma was feasible and safe and may allow survival with good local control of lung metastases.